STOCK TITAN

Seer to Present at the Cowen 43rd Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Seer, a life sciences company specializing in proteomics, announced participation in the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 8, 2023. The company’s management will engage in a fireside chat and Q&A session at 9:50 a.m. Eastern Time. Investors can access the live webcast via Seer's website, with an archived replay available post-conference. Seer’s innovative Proteograph Product Suite facilitates deep proteomic analysis efficiently and is designed for laboratory use. This suite is not intended for diagnostic procedures and aims to enhance research capabilities in proteomics.

Positive
  • None.
Negative
  • None.

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Cowen 43rd Annual Health Care Conference in Boston, MA.

Seer’s management is scheduled to participate in a fireside chat and Q&A session on Wednesday, March 8th at 9:50 a.m. Eastern Time / 6:50 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio


FAQ

What is Seer's participation in the Cowen 43rd Annual Health Care Conference?

Seer will participate in a fireside chat and Q&A session on March 8, 2023, at 9:50 a.m. Eastern Time.

How can I access the Cowen conference webcast for Seer?

The live webcast can be accessed through the Investor section of Seer's website at investor.seer.bio.

What is the focus of Seer’s Proteograph Product Suite?

The Proteograph Product Suite is designed for deep, unbiased proteomic analysis and is tailored for research purposes only.

When will the archived replay of Seer's conference session be available?

An archived replay of the session will be available on Seer's website following the conference.

Seer, Inc.

NASDAQ:SEER

SEER Rankings

SEER Latest News

SEER Stock Data

135.33M
54.92M
4.76%
68.86%
1.22%
Biotechnology
Laboratory Analytical Instruments
Link
United States of America
REDWOOD CITY